Association of four DNA polymorphisms with acute rejection after kidney transplantation

Transplant International

Volumn 21, Issue 9, 2008, Pages 879-891

  Grinyó, Josep ^a   Vanrenterghem, Yves ^b   Nashan, Björn ^c   Vincenti, Flavio ^d   Ekberg, Henrik ^e   Lindpaintner, Klaus ^f   Rashford, Michelle ^g   Nasmyth Miller, Clare ^g   Voulgari, Athina ^g   Spleiss, Olivia ^f   Truman, Matthew ^g   Essioux, Laurent ^f  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LUND UNIVERSITY   (Sweden)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Acute rejection; Kidney transplantation; Single nucleotide polymorphism

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DACLIZUMAB; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE 1; INOSINATE DEHYDROGENASE 2; INTERLEUKIN 10; INTERLEUKIN 2; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT REJECTION; ADULT; ALLELE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GENE LINKAGE DISEQUILIBRIUM; HOMOZYGOSITY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

FEMALE; GRAFT REJECTION; HUMANS; IMP DEHYDROGENASE; INTERLEUKIN-10; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49649106273     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2008.00679.x     Document Type: Article

References (53)

1. Fekete A, Viklicky O, Hubacek JA, et al. Association between heat shock protein 70s and toll-like receptor polymorphisms with long-term renal allograft survival. Transpl Int 2006 19 : 190.
2. Krüger B, Böger CA, Schröppel B, et al. Impact of NOD2/CARD15 haplotypes on the outcome after kidney transplantation. Transpl Int 2007 20 : 600.
3. Hesselink DA, van Gelder T, van Schaik RH. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 2005 6 : 323.
4. Hoffmann SC, Stanley EM, Darrin Cox E, et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28- stimulated peripheral blood lymphocytes. Transplantation 2001 72 : 1444.
5. Suarez A, Castro P, Alonso R, et al. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 2003 75 : 711.
6. Marshall SE, Welsh KI. The role of cytokine polymorphisms in rejection after solid organ transplantation. Genes Immun 2001 2 : 297.
7. Glander P, Hambach P, Braun KP, et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004 4 : 2045.
8. Benigni A, Bruzzi I, Mister M, et al. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney Int 1999 55 : 674.
9. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study. Am J Transplant 2007 7 : 560.
10. Germer S, Higuchi R. Single-tube genotyping without oligonucleotide probes. Genome Res 1999 9 : 72.
11. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001 27 : 383.
12. National Center for Biotechnology Information. Single Nucleotide Polymorphism: CSHL-HAPMAP. 2006 May 25. Available at: http://www.ncbi.nlm.nih. gov/SNP/snp_viewTable.cgi?pop=1409 (accessed 8 January 2008).
13. National Center for Biotechnology Information. Single Nucleotide Polymorphism: SNP500CANCER. 2006 May 25. Available at: http://www.ncbi.nlm.nih. gov/projects/SNP/snp_viewTable.cgi?pop=775 (accessed 8 January 2008).
14. National Center for Biotechnology Information. Single Nucleotide Polymorphism: EGP_SNPS. 2006 May 25. Available at: http://www.ncbi.nlm.nih.gov/ projects/SNP/snp_viewTable.cgi?pop=1473 (accessed 8 January 2008).
15. National Center for Biotechnology Information. Single Nucleotide Polymorphism: IIPGA-WEISS-MARTINEZ. 2006 May 25. Available at: http://www.ncbi.nlm.nih.gov/projects/SNP/snp_viewTable.cgi?pop=847 (accessed 8 January 2008).
16. Thervet E, Legendre C, Beaune P, et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 2005 6 : 37.
17. Yates CR, Zhang W, Song P, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003 43 : 555.
18. Zheng HX, Zeevi A, McCurry K, et al. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl Immunol 2005 14 : 37.
19. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005 5 : 987.
20. Vannozzi F, Filipponi F, Di Paolo A, et al. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. Transplant Proc 2004 36 : 2787.
21. Kaminski ER, Kaminski A, Bending MR, et al. In vitro cytokine profiles and their relevance to rejection following renal transplantation. Transplantation 1995 60 : 703.
22. Warle MC, Farhan A, Metselaar HJ, et al. Cytokine gene polymorphisms and acute human liver graft rejection. Liver Transpl 2002 8 : 603.
23. Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003 349 : 2201.
24. Burlingham WJ, O'Connell PJ, Jacobson LM, et al. Tumor necrosis factor-alpha and tumor growth factor-beta1 genotype: partial association with intragraft gene expression in two cases of long-term peripheral tolerance to a kidney transplant. Transplantation 2000 69 : 1527.
25. Baan CC, Balk AH, Holweg CT, et al. Renal failure after clinical heart transplantation is associated with the TGF-beta 1 codon 10 gene polymorphism. J Heart Lung Transplant 2000 19 : 866.
26. Sankaran D, Asderakis A, Ashraf S, et al. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int 1999 56 : 281.
27. Alakulppi NS, Kyllonen LE, Jantti VT, et al. Cytokine gene polymorphisms and risks of acute rejection and delayed graft function after kidney transplantation. Transplantation 2004 78 : 1422.
28. Longmate JA. Complexity and power in case-control association studies. Am J Hum Genet 2001 68 : 1229.
29. Cordell HJ, Clayton DG. A unified stepwise regression procedure for evaluating the relative effects of polymorphisms within a gene using case/control or family data: application to HLA in type 1 diabetes. Am J Hum Genet 2002 70 : 124.
30. Schaid DJ, Rowland CM, Tines DE, et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002 70 : 425.
31. Lake SL, Lyon H, Tantisira K, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003 55 : 56.
32. Weir BS. Genetic Data Analysis II. Sunderland, MA, USA : Sinauer Associates, 1996.
33. R Development Core Team R 2.2.1. In : R: A Language and Environment for Statistical Computing R Foundation for Statistical Computing. Austria : Vienna, 2006. Available at: http://www.R-project.org (accessed 3 December 2007).
34. Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Pharmacogenetics of Membrance Transporters Investigators. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003 13 : 481.
35. Tang K, Ngoi SM, Gwee PC, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002 12 : 437.
36. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000 97 : 3473.
37. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002 359 : 30.
38. Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001 18 : 1400.
39. Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003 14 : 1889.
40. Mai I, Stormer E, Goldammer M, et al. MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J Clin Pharmacol 2003 43 : 1101.
41. von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001 47 : 1048.
42. Anglicheau D, Thervet E, Etienne I, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004 75 : 422.
43. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995 17 : 681.
44. Marshall SE, McLaren AJ, Haldar NA, et al. The impact of recipient cytokine genotype on acute rejection after renal transplantation. Transplantation 2000 70 : 1485.
45. Hobbs K, Negri J, Klinnert M, et al. Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma. Am J Respir Crit Care Med 1998 158 : 1958.
46. Steinke JW, Barekzi E, Hagman J, et al. Functional analysis of -571 IL-10 promoter polymorphism reveals a repressor element controlled by sp1. J Immunol 2004 173 : 3215.
47. Kida Y. Interleukin-10 and graft-versus-host disease. N Engl J Med 2004 350 : 1361.
48. Shin HD, Winkler C, Stephens JC, et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA 2000 97 : 14467.
49. Kurreeman FA, Schonkeren JJ, Heijmans BT, et al. Transcription of the IL10 gene reveals allele-specific regulation at the mRNA level. Hum Mol Genet 2004 13 : 1755.
50. Morgun A, Shulzhenko N, Gerbase-DeLima M. IL-10 gene polymorphisms in transplantation. In : Marincola F, ed. Interleukin-10 : Landes Bioscience Publ, 2006. Available at: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=eurekah. chapter.25666 (accessed 8 January 2008).
51. Pepe MS, Janes H, Longton G, et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004 159 : 882.
52. Wacholder S, Chanock S, Montserrat G-C, et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology study. J Natl Cancer Inst 2004 96 : 434.
53. Thomas DC, Clayton DG. Betting odds and genetic associations. J Natl Cancer Inst 2004 96 : 421.